Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FEMASYS INCFEMY · Entity 7510 | Chief Reg & Clinical Officer | January 28, 2025 | January 31, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FEMASYS INC
Report date January 28, 2025 · Filed January 31, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 · Expires 2035-01-28 | Direct | 55,090 |
Reported balance
After 2025-01-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-28 · Grant · Acquired 55,090 · Balance 55,090 F1: The shares underlying the stock option vest equally in installments over 3 years beginning on January 28, 2025, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 · Expires 2035-01-28 | Direct | 28,682 |
Reported balance
After 2025-01-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-01-28 · Grant · Acquired 28,682 · Balance 28,682 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 · Expires 2035-01-28 | Direct | 23,600 |
Reported balance
After 2025-01-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-01-28 · Grant · Acquired 23,600 · Balance 23,600 F2: The shares underlying the stock option vest equally in installments over 4 years beginning on January 28, 2025, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option vest equally in installments over 3 years beginning on January 28, 2025, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date.
F2: The shares underlying the stock option vest equally in installments over 4 years beginning on January 28, 2025, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 28, 2025 Filed Jan 31, 2025 00:33 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 23,600 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001140361-25-002476 · form4.xml · derivative · entry 3 Thomas Christine E · CIK 0001950745 · Chief Reg & Clinical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,600 Underlying: Common Stock · 23,600 shares Expires 2035-01-28 F2 · derivative.exercise_date: The shares underlying the stock option vest equally in installments over 4 years beginning on January 28, 2025, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date. Read SEC document |
| January 28, 2025 Filed Jan 31, 2025 00:33 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 28,682 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001140361-25-002476 · form4.xml · derivative · entry 2 Thomas Christine E · CIK 0001950745 · Chief Reg & Clinical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,682 Underlying: Common Stock · 28,682 shares Expires 2035-01-28 Read SEC document |
| January 28, 2025 Filed Jan 31, 2025 00:33 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 55,090 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001140361-25-002476 · form4.xml · derivative · entry 1 Thomas Christine E · CIK 0001950745 · Chief Reg & Clinical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,090 Underlying: Common Stock · 55,090 shares Expires 2035-01-28 F1 · derivative.exercise_date: The shares underlying the stock option vest equally in installments over 3 years beginning on January 28, 2025, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:42 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 32,600 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001140361-24-005352 · form4.xml · derivative · entry 1 Thomas Christine E · CIK 0001950745 · SVP, Regulatory & Clinical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,600 Underlying: Common Stock · 32,600 shares Expires 2034-02-01 F1 · derivative.exercise_date: The shares underlying the stock option vest equally in installments over 4 years beginning on February 1, 2024, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date. Read SEC document |
| October 10, 2023 Filed Nov 2, 2023 01:40 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001140361-23-050942 · form4.xml · derivative · entry 1 Thomas Christine E · CIK 0001950745 · SVP, Regulatory & Clinical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-10-10 F1 · derivative.exercise_date: The shares underlying the stock option vest equally in installments over 4 years beginning on October 10, 2024, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date. Read SEC document |
| October 10, 2022 Filed Oct 17, 2022 20:48 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001140361-22-037412 · form4.xml · derivative · entry 1 Thomas Christine E · CIK 0001950745 · SVP, Regulatory & Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-10-10 F1 · derivative.exercise_date: The shares underlying the stock option vest equally in installments over 4 years beginning on October 10, 2023, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.